Analysts See $-0.42 EPS for Seattle Genetics, Inc. (SGEN)

October 13, 2017 - By Adrian Erickson

 Analysts See $ 0.42 EPS for Seattle Genetics, Inc. (SGEN)
Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.20, from 1.5 in 2017Q1. It turned negative, as 30 investors sold Seattle Genetics, Inc. shares while 75 reduced holdings. 48 funds opened positions while 89 raised stakes. 137.48 million shares or 0.82% less from 138.62 million shares in 2017Q1 were reported.
Cwm Limited Liability Corp invested in 200 shares or 0% of the stock. Baker Bros Advsr Ltd Partnership reported 45.73 million shares or 20.68% of all its holdings. Deutsche Bankshares Ag holds 801,493 shares or 0.03% of its portfolio. 35,093 are held by Opus Point Prtnrs Management Ltd Llc. Moreover, Sumitomo Mitsui Asset Communications Limited has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Hsbc Public Limited Com has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). reported 2.72M shares. Platinum Investment Ltd accumulated 32,000 shares or 0.04% of the stock. Next Fincl Grp reported 100 shares stake. Eqis Capital Management stated it has 26,258 shares. Gsa Cap Partners Llp holds 0.02% or 6,756 shares in its portfolio. Brown Brothers Harriman And Company invested in 3,000 shares. World Asset Mngmt Incorporated invested in 0.01% or 4,326 shares. National Bank & Trust Of Mellon accumulated 426,129 shares. Gam Holdg Ag reported 4,564 shares stake.

Since May 5, 2017, it had 0 buys, and 3 insider sales for $2.20 million activity. $892,897 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by SIEGALL CLAY B. Another trade for 10,000 shares valued at $625,922 was sold by HIMES VAUGHN B.

Analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to report $-0.42 EPS on October, 26.They anticipate $0.19 EPS change or 82.61 % from last quarter’s $-0.23 EPS. After having $-0.39 EPS previously, Seattle Genetics, Inc.’s analysts see 7.69 % EPS growth. The stock increased 0.49% or $0.3 during the last trading session, reaching $61.77. About 1.99M shares traded or 82.57% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since October 13, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 16 analysts covering Seattle Genetics (NASDAQ:SGEN), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. Seattle Genetics had 45 analyst reports since July 31, 2015 according to SRatingsIntel. As per Monday, June 19, the company rating was maintained by Cowen & Co. The firm has “Hold” rating by SunTrust given on Tuesday, October 3. Jefferies maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Tuesday, September 12 with “Buy” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by J.P. Morgan on Thursday, June 8. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by Needham on Friday, September 15. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by H.C. Wainwright on Monday, June 19. The company was maintained on Monday, July 24 by Oppenheimer. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Oppenheimer on Tuesday, August 29. The rating was downgraded by Credit Suisse to “Neutral” on Monday, December 12. The rating was downgraded by Cantor Fitzgerald on Wednesday, July 27 to “Hold”.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $8.83 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Nasdaq.com which released: “Seattle Genetics’ Adcetris Gets Breakthrough Therapy Status” on October 03, 2017, also Nasdaq.com with their article: “Seattle Genetics Inks Clinical Collaborations for Cancer Drug” published on October 12, 2017, Businesswire.com published: “Seattle Genetics to Host Conference Call and Webcast Discussion of Third …” on October 05, 2017. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Zacks.com and their article: “Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher October 03, 2017” published on October 03, 2017 as well as Seekingalpha.com‘s news article titled: “Seattle Genetics: Good Time To Buy Based On Adcetris Label Expansion” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: